Drug transporters and anthracycline-induced cardiotoxicity

Pharmacogenomics. 2018 Jul 1;19(11):883-888. doi: 10.2217/pgs-2018-0056. Epub 2018 Jul 11.

Abstract

The solute carrier superfamily comprises of uptake transporters that can contribute to the absorption and elimination of a broad array of clinically important drugs. Recent studies have suggested that the tissue-specific expression of these transporters may have important consequences for an individual's susceptibility to drug-induced organ damage or to drug-drug interactions. Polymorphic variants have been identified in genes encoded by this family, and some of these have been associated with functional changes in transport function and response to anthracycline-induced toxicity and efficacy. Here, we review recent advances in the role solute carrier transporters play in anthracycline-induced cardiotoxicity, highlight potential implications of genetic variants that may contribute to drug response and discuss novel technologies to study mechanisms of anthracycline transport.

Keywords: anthracyclines; cardiomyocytes; cardiotoxicity; doxorubicin; organic cation transporters; solute carriers.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anthracyclines / adverse effects*
  • Biological Transport / genetics*
  • Cardiotoxicity / genetics*
  • Drug Interactions / genetics
  • Genetic Variation / genetics
  • Humans
  • Membrane Transport Proteins / genetics*

Substances

  • Anthracyclines
  • Membrane Transport Proteins